BioLife Solutions
Stock Forecast, Prediction & Price Target
BioLife Solutions (BLFS) stock Price Target by analysts
$30
Potential upside: 22.34%
BioLife Solutions price prediction
What is BioLife Solutions stock analysts` prediction?
BioLife Solutions stock forecast: Based on 1 Wall Street analysts` predicted price targets for BioLife Solutions in the last 3 months, the avarage price target is $30, with a high forecast of $NaN. The average price target represents a 22.34% change from the last price of $24.52.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
BioLife Solutions stock Price Target by analysts
Full breakdown of analysts given BioLife Solutions price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Jacob Johnson Stephens | 0% 0/1 | 11 months ago | $30 22.34% upside | $21.58 | StreetInsider | Previous targets (0) |
Matt Hewitt Craig-Hallum | 0% 0/1 | about 1 year ago | $30 22.34% upside | $25.25 | TheFly | Previous targets (0) |
Matthew Stanton Jefferies | 0% 0/1 | over 1 year ago | $22 -10.27% downside | $17.32 | StreetInsider | Previous targets (0) |
BioLife Solutions Financial Estimates
BioLife Solutions Revenue Estimates
BioLife Solutions EBITDA Estimates
BioLife Solutions Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $119.15M N/A | $161.75M 35.75% | $143.27M -11.42% | Avg: $121.50M Low: $108.33M High: $134.66M avg. -15.19% | Avg: $156.08M Low: $144.17M High: $174.02M avg. 28.46% | Avg: $227.06M Low: $209.74M High: $253.17M avg. 45.47% | Avg: $288.88M Low: $266.85M High: $322.10M avg. 27.22% |
Net Income
% change YoY
| $-8.38M N/A | $-139.80M -1567.72% | $-66.42M 52.48% | Avg: $-15.05M Low: $-28.41M High: $-3.49M avg. 77.33% | Avg: $5.64M Low: $-6.55M High: $17.48M avg. 137.46% | Avg: $48.96M Low: $44.11M High: $56.28M avg. 768.10% | Avg: $87.00M Low: $78.37M High: $100.00M avg. 77.67% |
EBITDA
% change YoY
| $-23.98M N/A | $-29.51M -23.05% | $-45.23M -53.28% | Avg: $-17.59M Low: $-19.50M High: $-15.69M avg. 61.09% | Avg: $-22.60M Low: $-25.20M High: $-20.88M avg. -28.46% | Avg: $-32.88M Low: $-36.67M High: $-30.38M avg. -45.47% | Avg: $-41.84M Low: $-46.65M High: $-38.65M avg. -27.22% |
EPS
% change YoY
| -$0.22 N/A | -$3.29 -1395.45% | -$1.52 53.79% | Avg: -$0.32 Low: -$0.65 High: -$0.08 avg. 78.68% | Avg: $0.13 Low: -$0.15 High: $0.4 avg. 138.58% | Avg: $1.12 Low: $1.01 High: $1.29 avg. 796.00% | Avg: $1.99 Low: $1.79 High: $2.29 avg. 77.67% |
Operating Expenses
% change YoY
| $68.11M N/A | $93.73M 37.61% | $117.57M 25.43% | Avg: $56.92M Low: $50.76M High: $63.09M avg. -51.58% | Avg: $73.13M Low: $67.55M High: $81.54M avg. 28.46% | Avg: $106.39M Low: $98.27M High: $118.62M avg. 45.47% | Avg: $135.35M Low: $125.03M High: $150.92M avg. 27.22% |
FAQ
What is BioLife Solutions stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 265.14% in 2025-2028.
We have gathered data from 4 analysts. Their low estimate is -28.41M, average is -15.05M and high is -3.49M.
What is BioLife Solutions stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 21.49% in 2025-2028.
We have gathered data from 5 analysts. Their low revenue estimate is $108.33M, average is $121.50M and high is $134.66M.
What is BioLife Solutions stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 272.73% in 2025-2028.
We have gathered data from 4 analysts. Their low earnings per share estimate is -$0.65, average is -$0.32 and high is $-0.08.
What is the best performing analyst?
In the last twelve months 1 analysts have been covering BioLife Solutions stock. The most successful analyst is Jacob Johnson.